• Loading metrics

Chlamydia trachomatis and human herpesvirus 6 infections in ovarian cancer—Casual or causal?

Chlamydia trachomatis and human herpesvirus 6 infections in ovarian cancer—Casual or causal?

  • Nitish Gulve, 
  • Thomas Rudel

Ovarian cancer is one of the most lethal gynecological malignancies in the world. In the United States, more than 20,000 cases of ovarian cancer average every year, causing more than 14,000 deaths per year ( This high percentage of mortality arises predominantly due to the silent nature of the disease. Ovarian cancer is diagnosed mostly in the late stages thus earning the disease its name—"Silent killer.” It is therefore of utmost importance to identify any markers that will allow early detection of ovarian cancer.

The National Cancer Institute associates 15%–20% of all cancer with infectious agents. Studies in the past have shown the presence of several viral and bacterial markers in ovarian cancer samples [1, 2]. Understanding the molecular mechanisms of pathogenesis of these oncogenic pathogens may therefore enable early intervention in treatment and care of ovarian cancer patients. In this brief review, we endeavor to highlight the role that coinfection of human herpesvirus 6 (HHV-6) and Chlamydia trachomatis may play in initiation and progression of ovarian cancer and propose a theory that may justify their presence in ovarian cancer tissues, thus enabling a directed therapeutic approach.

C. trachomatis is an obligate intracellular, gram-negative bacterium that is transmitted sexually. More than 2.8 million cases are registered in the US alone [3]. However, the actual number is believed to be much higher, owing to the asymptomatic nature of most C. trachomatis infections. C. trachomatis has a 48–72 hour life cycle in which it infects the cells, replicates, and exits by host cell lysis. During its developmental cycle, C. trachomatis cycles between 2 forms—infectious elementary bodies and replicative reticulate bodies (RB). Its presence in the cell is confined to a vacuole- inclusion. One characteristic of C. trachomatis infection is its ability to persist in an individual for months up to years. It modulates the host-cell signaling pathways, interacts with various organelles, and evades apoptosis to enable the completion of its developmental cycle [4]. In its pursuit of survival, however, C. trachomatis infection induces reactive oxygen species (ROS) production via the NADPH and NOD-like receptor family member X1 (NLRX1) pathways [5]. ROS further leads to oxidative damage of DNA, which is further repaired by base excision repair (BER) and nucleotide excision repair (NER) pathways. Recent studies have shown that C. trachomatis impairs BER of damaged DNA by down-regulating polymerase beta [6]. Deficiency in BER pathway enables the cells to acquire tumorigenic properties [7]. Inefficient BER leads to accumulation of single strand breaks which eventually lead to double strand breaks in the DNA [8]. Telomeres, the protective molecular caps on chromosomes, are damaged through induced telomere shortening during C. trachomatis infection [9]. C. trachomatis also affects the DNA damage response and associated signaling of DNA double strand break and telomere repair [1012]. During C. trachomatis infection, the host cell encounters DNA damage and suffers impaired repair thereby giving rise to the underlying foundation of the prominent cancer hallmark—genomic instability.

HHV-6 is a betaherpesvirus that has a double-stranded DNA genome. It infects nearly every individual by the age of 2 years. Its unique ability of integration in host telomeres enables it to maintain a lifelong latency in the infected individual. It mediates this integration through homologous recombination between its direct repeat (DR) sequences and host telomeric sequences. This integrated state is termed as chromosomally integrated HHV-6 (ciHHV-6) [13]. This integrated virus can be transmitted vertically in a mendelian fashion and is then termed as inherited chromosomally integrated HHV-6 (iciHHV-6). iciHHV-6 occurs in 1% of the general population in which at least 1 copy of the virus is present in every nucleated cell of the body [14]. This integrated virus may reactivate further in the lifetime of an individual by telomere-circle formation mechanism, which causes the excision of virus and its replication and/or transcription [9]. HHV-6 reactivation can occur due to many reasons, predominantly by stress and immunosuppression. Reactivation of HHV-6 is associated with a wide range of disorders [1517]. Interestingly, DR sequences are able to integrate within the host genome even in absence of the viral genome. Both in vivo and in vitro studies have shown that viral DRs are capable of integrating in telomeric, as well as in nontelomeric, regions of host chromosomes [18]. Here, the viral DRs were shown to integrate in the intronic regions of gene encoding angiogenesis factor AGGF1 and G alpha interacting protein GAIP [18]. Integration of viral elements in the intronic regions may lead to enhanced gene expression [19]. This transposon-like feature of HHV-6 DR bears the potential of disrupting the regulation of important genes of human genome. The randomness of DR integration makes it an even more lethal cause of genomic instability. Recently, early reactivation or transactivation of HHV-6 has been highlighted by identifying small noncoding viral RNAs (sncRNAs) and their effect on the host transcriptome [20]. The viral DR encoded DR7 protein is known to bind tumor suppressor p53 and inhibit its nuclear translocation by sequestering it in cytoplasm. This strategy of HHV-6 to evade apoptosis may suffice as an initial trigger towards tumorigenesis [21].

C. trachomatis and HHV-6 share an interesting dynamic of coinfection. Coinfection of a C. trachomatis infected cell with HHV-6 induces C. trachomatis persistence in vitro [22], whereas C. trachomatis infection of a latent HHV-6 cell line induces reactivation of the virus [9]. Both these scenarios are detrimental to the genome stability of the host cell. Persistence of C. trachomatis would mean DNA damage over an extended period of time, whereas reactivation of virus may induce production of viral sncRNAs, and random DR integration may severally hamper genome stability (Fig 1). C. trachomatis, although being associated with ovarian cancer for nearly a decade now, is mostly studied in its active infectious state. The persistence model of C. trachomatis is seldom focused upon by researchers. Time and again, epidemiological studies employing extensive controls have pinpointed past C. trachomatis infections to ovarian cancer [23]. A recent study using PathoChip array was employed to identify various pathogenic signatures in ovarian cancer samples. The hybridization signal to pathogen genomic material was compared with both matched and unmatched control samples. Astonishingly, high HHV-6 signals were detected in ovarian cancer but not in either of the control samples. Chlamydia was present with a low prevalence in the same study [1].

Fig 1. Consequences of C. trachomatis and HHV-6 coinfection.

C. trachomatis infection of an iciHHV-6 cell leads to (a) DNA damage due to impaired BER and other pathways of DNA damage signaling and (b) HHV-6 reactivation or transactivation and may also lead to transcription of viral sncRNAs. C. trachomatis changes the epigenetic markup of host cells causing global heterochromatin formation (c). HHV-6 reactivation or transactivation on the other hand may cause (c) integration of DR sequences at regions in host genome that are “active” during C. trachomatis infection. Integration at important open reading frames of important genes such as PI3K or hTERT may promote transformation of the cell. HHV-6 DR encodes an oncoprotein DR7, which binds and sequesters p53 in the cytoplasm (d). p53 is also down-regulated in C. trachomatis -infected cells by various mechanisms. BER, base excision repair; HHV-6, human herpesvirus 6; iciHHV-6; inherited chromosomally integrated HHV-6; sncRNAs, small noncoding viral RNAs.

Could these pathogens act synergistically and bring about transformation in ovarian cells? Several studies have reported that pathogens do co-occur and coinfect, and such coinfections are implicated in different types of cancer. C. trachomatis has been known to be an important factor in determining the course of Human Papillomavirus (HPV) infection and C. trachomatis/HPV coinfection may cause cervical cancer [2426]. Plasmodium falciparum and Epstein Barr virus (EBV) coinfection is implicated in Burkitt Lymphoma in children in equatorial Africa [27]. Helicobacter pylori and Hepatitis C virus (HCV) are often implicated as coinfecting pathogens in a range of abnormalities, including liver cirrhosis, non-Hodgkin’s lymphoma, and gastric adenocarcinoma [2830]. However, currently there is no study focusing on HHV-6 and C. trachomatis coinfections in cancer samples. It is probably time to strip HHV-6 off its “benign” label and consider its coinfection with C. trachomatis and/or other pathogens for further in-depth studies. Identification of prevalence rates of coinfection in ovarian cancer samples may enable researchers to step-up the in vitro studies and move towards more robust models to study molecular pathogenesis of coinfection. C. trachomatis down-regulates p53 by various mechanisms to evade apoptosis [31, 32]. Hence, therapies directed towards stabilizing p53 during infection could be further explored to reduce C. trachomatis-induced onset of ovarian cancer. C. trachomatis also changes the miRNA profile of the host cell such as by up-regulating miR-30c or miR-499a targeting DRP-1 and polymerase beta, respectively [6, 33]. Both miRNAs also target p53. Therefore, research on miRNA inhibitors as a preventive measure during infection could be considered as another approach. Strong correlation of past infection with C. trachomatis with nearly absent or low prevalence of pathogen in the cancer tissue suggests the ability of this pathogen to alter cells in such a way that further escalates and leads to transformation even after the pathogen is cleared. Down-regulation of p53 and induction of DNA damage are characteristics of C. trachomatis infection that would fit almost perfectly with this hypothesis. However, preexisting genomic malady such as iciHHV-6 could further enhance the magnitude of C. trachomatis-induced genomic instability and mediated oncogenesis. C. trachomatis causes global heterochromatin formation of host genome [10]. Therefore, when most of the genome is inaccessible, HHV-6 reactivation during C. trachomatis infection may lead to DR integration at chromosomal regions that are “active” or accessible. Genes, which are up-regulated during C. trachomatis infection, therefore, form tangible targets for DR integration. Genetic counseling for iciHHV-6 status owing to the hazardous nature of DR integration should therefore be considered for predisposed individuals. One additional marker enabling early detection of ovarian cancer will go a long way in reducing the burden of the disease and allowing a directed therapeutic approach.

Decades have passed after the Hippocratic dyad explaining that health is achieved by man-environment harmony, and that dyad has since been upgraded to a triad to include the etiological agent. Although many infectious agents causing cancer such as HPV, EBV, or Helicobacter pylori have been well-studied in terms of their molecular mechanism causing cancer, others like C. trachomatis and HHV-6, albeit strongly, are merely associated with cancer. It is perhaps time to design more comprehensive studies and harness “omics” approaches to understand the possibility of these coinfections in ovarian cancer and subsequently identify the molecular mechanisms.


  1. 1. Banerjee S, Alwine JC, Coukos G, Tian T, Wei Z, Shih N, et al. The ovarian cancer oncobiome. Oncotarget. 2017;8(22):36225–45. pmid:28410234
  2. 2. Shanmughapriya S, Senthilkumar G, Vinodhini K, Das BC, Vasanthi N, Natarajaseenivasan K. Viral and bacterial aetiologies of epithelial ovarian cancer. Eur J Clin Microbiol Infect Dis. 2012;31(9):2311–7. pmid:22402815
  3. 3. Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–93. pmid:23403598
  4. 4. Elwell C, Mirrashidi K, Engel J. Chlamydia cell biology and pathogenesis. Nature Reviews Microbiology. 2016;14(6):385–400. pmid:27108705
  5. 5. Abdul-Sater AA, Saïd-Sadier N, Lam VM, Singh B, Pettengill MA, Soares F, et al. Enhancement of Reactive Oxygen Species Production and Chlamydial Infection by the Mitochondrial Nod-like Family Member NLRX1. Journal of Biological Chemistry. 2010;285(53):41637–45. pmid:20959452
  6. 6. Gulve N, Prusty BK, Rudel T. Chlamydia trachomatis impairs host base excision repair by downregulating polymerase beta. Cell Microbiol. 2019;21(4):e12986. pmid:30471195
  7. 7. Markkanen E, Fischer R, Ledentcova M, Kessler BM, Dianov GL. Cells deficient in base-excision repair reveal cancer hallmarks originating from adjustments to genetic instability. Nucleic Acids Res. 2015;43(7):3667–79. pmid:25800737
  8. 8. Kuzminov A. Single-strand interruptions in replicating chromosomes cause double-strand breaks. Proc Natl Acad Sci U S A. 2001;98(15):8241–6. pmid:11459959
  9. 9. Prusty BK, Krohne G, Rudel T. Reactivation of chromosomally integrated human herpesvirus-6 by telomeric circle formation. PLoS Genet. 2013;9(12):e1004033. pmid:24367281
  10. 10. Chumduri C, Gurumurthy Rajendra K, Zadora Piotr K, Mi Y, Meyer Thomas F. Chlamydia Infection Promotes Host DNA Damage and Proliferation but Impairs the DNA Damage Response. Cell Host & Microbe. 2013;13(6):746–58.
  11. 11. Mi Y, Gurumurthy RK, Zadora PK, Meyer TF, Chumduri C. Chlamydia trachomatis Inhibits Homologous Recombination Repair of DNA Breaks by Interfering with PP2A Signaling. MBio. 2018;9(6).
  12. 12. Padberg I, Janssen S, Meyer TF. Chlamydia trachomatis inhibits telomeric DNA damage signaling via transient hTERT upregulation. Int J Med Microbiol. 2013;303(8):463–74. pmid:23830072
  13. 13. Arbuckle JH, Medveczky MM, Luka J, Hadley SH, Luegmayr A, Ablashi D, et al. The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. Proceedings of the National Academy of Sciences. 2010;107(12):5563–8.
  14. 14. Hall CB, Caserta MT, Schnabel K, Shelley LM, Marino AS, Carnahan JA, et al. Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics. 2008;122(3):513–20. pmid:18762520
  15. 15. Carbone I, Lazzarotto T, Ianni M, Porcellini E, Forti P, Masliah E, et al. Herpes virus in Alzheimer's disease: relation to progression of the disease. Neurobiology of Aging. 2014;35(1):122–9. pmid:23916950
  16. 16. Gravel A, Dubuc I, Morissette G, Sedlak RH, Jerome KR, Flamand L. Inherited chromosomally integrated human herpesvirus 6 as a predisposing risk factor for the development of angina pectoris. Proc Natl Acad Sci U S A. 2015;112(26):8058–63. pmid:26080419
  17. 17. Ogata M, Satou T, Kadota J, Saito N, Yoshida T, Okumura H, et al. Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study. Clin Infect Dis. 2013;57(5):671–81. pmid:23723198
  18. 18. Gulve N, Frank C, Klepsch M, Prusty BK. Chromosomal integration of HHV-6A during non-productive viral infection. Sci Rep. 2017;7(1):512. pmid:28360414
  19. 19. Ikeda T, Shibata J, Yoshimura K, Koito A, Matsushita S. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy. J Infect Dis. 2007;195(5):716–25. pmid:17262715
  20. 20. Prusty BK, Gulve N, Chowdhury SR, Schuster M, Strempel S, Descamps V, et al. HHV-6 encoded small non-coding RNAs define an intermediate and early stage in viral reactivation. NPJ Genom Med. 2018;3:25. pmid:30210807
  21. 21. Lacroix A, Collot-Teixeira S, Mardivirin L, Jaccard A, Petit B, Piguet C, et al. Involvement of human herpesvirus-6 variant B in classic Hodgkin's lymphoma via DR7 oncoprotein. Clin Cancer Res. 2010;16(19):4711–21. pmid:20858841
  22. 22. Prusty BK, Bohme L, Bergmann B, Siegl C, Krause E, Mehlitz A, et al. Imbalanced oxidative stress causes chlamydial persistence during non-productive human herpes virus co-infection. PLoS ONE. 2012;7(10):e47427. pmid:23077614
  23. 23. Das M. Chlamydia infection and ovarian cancer risk. The Lancet Oncology. 2018;19(7).
  24. 24. Nonato DR, Alves RR, Ribeiro AA, Saddi VA, Segati KD, Almeida KP, et al. Prevalence and factors associated with coinfection of human papillomavirus and Chlamydia trachomatis in adolescents and young women. Am J Obstet Gynecol. 2016;215(6):753 e1–e9.
  25. 25. Seraceni S, Campisciano G, Contini C, Comar M. HPV genotypes distribution in Chlamydia trachomatis co-infection in a large cohort of women from north-east Italy. J Med Microbiol. 2016;65(5):406–13. pmid:26944507
  26. 26. Tota JE, Chevarie-Davis M, Richardson LA, deVries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Preventive Medicine. 2011;53:S12–S21. pmid:21962466
  27. 27. Moormann AM, Snider CJ, Chelimo K. The company malaria keeps. Current Opinion in Infectious Diseases. 2011;24(5):435–41. pmid:21885920
  28. 28. Kountouras J, Zavos C, Giorgakis N, Tantsi N, Kotsani M. Additional data on Helicobacter pylori and hepatitis C virus infections and lymphoma association. Eur J Intern Med. 2014;25(1):e7–8. pmid:23651954
  29. 29. Pogorzelska J, Lapinska M, Kalinowska A, Lapinski TW, Flisiak R. Helicobacter pylori infection among patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2017;29(10):1161–5. pmid:28700364
  30. 30. Zucca E, Roggero E, Maggi-Solca N, Conconi A, Bertoni F, Reilly I, et al. Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin’s lymphoma patients in Southern Switzerland. Haematologica. 2000;85:147–53. pmid:10681721
  31. 31. González E, Rother M, Kerr MC, Al-Zeer MA, Abu-Lubad M, Kessler M, et al. Chlamydia infection depends on a functional MDM2-p53 axis. Nature Communications. 2014;5(1).
  32. 32. Siegl C, Prusty BK, Karunakaran K, Wischhusen J, Rudel T. Tumor suppressor p53 alters host cell metabolism to limit Chlamydia trachomatis infection. Cell Rep. 2014;9(3):918–29. pmid:25437549
  33. 33. Chowdhury SR, Reimer A, Sharan M, Kozjak-Pavlovic V, Eulalio A, Prusty BK, et al. Chlamydia preserves the mitochondrial network necessary for replication via microRNA-dependent inhibition of fission. The Journal of Cell Biology. 2017;216(4):1071–89. pmid:28330939